Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 5/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633929 | 1.00 | MAPT (0.37) | MAPTSMN1; SMN2L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL5633930 | 0.74 | PRMT5 (0.54) | MAPTKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL28290356 | 0.73 | KMT2A (0.43) | MAPTSMN1; SMN2L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL28290358 | 0.73 | KMT2A (0.43) | MAPTSMN1; SMN2L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL5634556 | 0.73 | CCR4 (0.52) | SMN1; SMN2L3MBTL1KMT2AALDH1A1KDM4E | |
| SCHEMBL981027 | 0.73 | KMT2A (0.41) | KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL1720326 | 0.73 | KMT2A (0.41) | KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL336604 | 0.73 | KMT2A (0.41) | KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL1787921 | 0.73 | KMT2A (0.41) | KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL981024 | 0.73 | KMT2A (0.41) | KMT2AALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186718-B2 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| EP-1421082-B1 | PIPERIDINYL-MORPHOLINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| US-20040204408-A1 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204408-A1 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | CCR5, CCR2, CXCR2 | MAPT 4299/4885SMN1; SMN2 3862/4885L3MBTL1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.